• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脑微胶质细胞活化在帕金森病 GBA 基因突变携带者中增加。

Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.

机构信息

Department of Clinical and Movement Neurosciences, Institute of Neurology, UCL, London, UK.

Institute of Health and Care Research, University of Plymouth Peninsula School of Medicine, Plymouth, UK.

出版信息

Mov Disord. 2021 Mar;36(3):774-779. doi: 10.1002/mds.28375. Epub 2020 Dec 5.

DOI:10.1002/mds.28375
PMID:33278043
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8048428/
Abstract

BACKGROUND

Glucocerebrosidase gene mutations are a common genetic risk factor for Parkinson's disease. They exhibit incomplete penetrance. The objective of the present study was to measure microglial activation and dopamine integrity in glucocerebrosidase gene mutation carriers without Parkinson's disease compared to controls.

METHODS

We performed PET scans on 9 glucocerebrosidase gene mutation carriers without Parkinson's disease and 29 age-matched controls. We measured microglial activation as C-(R)-PK11195 binding potentials, and dopamine terminal integrity with F-dopa influx constants.

RESULTS

The C-(R)-PK11195 binding potential was increased in the substantia nigra of glucocerebrosidase gene carriers compared with controls (Student t test; right, t = -4.45, P = 0.0001). Statistical parametric mapping also localized significantly increased C-(R)-PK11195 binding potential in the occipital and temporal lobes, cerebellum, hippocampus, and mesencephalon. The degree of hyposmia correlated with nigral C-(R)-PK11195 regional binding potentials (Spearman's rank, P = 0.0066). Mean striatal F-dopa uptake was similar to healthy controls.

CONCLUSIONS

In vivo C-(R)-PK11195 PET imaging detects neuroinflammation in brain regions susceptible to Lewy pathology in glucocerebrosidase gene mutation carriers without Parkinson's. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

摘要

背景

葡萄糖脑苷脂酶基因突变是帕金森病的常见遗传风险因素。它们表现出不完全外显率。本研究的目的是测量无帕金森病的葡萄糖脑苷脂酶基因突变携带者与对照组相比的小胶质细胞激活和多巴胺完整性。

方法

我们对 9 名无帕金森病的葡萄糖脑苷脂酶基因突变携带者和 29 名年龄匹配的对照者进行了 PET 扫描。我们测量了小胶质细胞的激活作为 C-(R)-PK11195 结合势,并用 F-多巴摄取常数测量多巴胺末端完整性。

结果

与对照组相比,葡萄糖脑苷脂酶基因突变携带者的黑质中 C-(R)-PK11195 结合势增加(学生 t 检验;右侧,t=-4.45,P=0.0001)。统计参数映射还定位了在枕叶和颞叶、小脑、海马体和中脑显著增加的 C-(R)-PK11195 结合势。嗅觉减退的程度与黑质 C-(R)-PK11195 区域结合势相关(Spearman 等级,P=0.0066)。纹状体的 F-多巴摄取率与健康对照组相似。

结论

体内 C-(R)-PK11195 PET 成像在无帕金森病的葡萄糖脑苷脂酶基因突变携带者中检测到易患路易体病理的大脑区域的神经炎症。© 2020 作者。运动障碍由 Wiley 期刊公司代表国际帕金森病和运动障碍协会出版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/056c/8048428/990dc3997faa/MDS-36-774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/056c/8048428/990dc3997faa/MDS-36-774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/056c/8048428/990dc3997faa/MDS-36-774-g001.jpg

相似文献

1
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.脑微胶质细胞活化在帕金森病 GBA 基因突变携带者中增加。
Mov Disord. 2021 Mar;36(3):774-779. doi: 10.1002/mds.28375. Epub 2020 Dec 5.
2
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.伴有和不伴有GBA突变的帕金森病中的葡萄糖脑苷脂酶活性
Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27.
3
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.氨溴索可改善葡萄糖脑苷脂酶突变相关帕金森病细胞的溶酶体生化特性。
Brain. 2014 May;137(Pt 5):1481-95. doi: 10.1093/brain/awu020. Epub 2014 Feb 25.
4
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.帕金森病中的 GBA 变异:临床、代谢组学和多模态神经影像学表型。
Mov Disord. 2020 Dec;35(12):2201-2210. doi: 10.1002/mds.28225. Epub 2020 Aug 27.
5
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.帕金森进展标志物倡议(PPMI)中无明显 LRRK2 和 GBA 突变携带者的临床和多巴胺转运体成像特征:一项横断面研究。
Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.
6
Cholinergic innervation topography in GBA-associated de novo Parkinson's disease patients.GBA 相关散发性帕金森病患者的胆碱能神经支配分布。
Brain. 2024 Mar 1;147(3):900-910. doi: 10.1093/brain/awad323.
7
White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations.帕金森病伴葡萄糖脑苷脂酶基因突变患者的脑白质异常。
Mov Disord. 2013 Jun;28(6):772-8. doi: 10.1002/mds.25397. Epub 2013 Feb 15.
8
Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.GBA 相关帕金森病的进展——病理学、临床表现与治疗
Neurochem Int. 2016 Feb;93:6-25. doi: 10.1016/j.neuint.2015.12.004. Epub 2015 Dec 30.
9
Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study.帕金森病中葡萄糖脑苷脂酶(GBA)突变的外显率:一项近亲队列研究。
Mov Disord. 2020 Nov;35(11):2111-2114. doi: 10.1002/mds.28200. Epub 2020 Aug 7.
10
Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers.在无症状 LRRK2 突变携带者中成像多巴胺功能和小胶质细胞。
J Neurol. 2020 Aug;267(8):2296-2300. doi: 10.1007/s00415-020-09830-3. Epub 2020 Apr 21.

引用本文的文献

1
Immune cell metabolic dysfunction in Parkinson's disease.帕金森病中的免疫细胞代谢功能障碍
Mol Neurodegener. 2025 Mar 24;20(1):36. doi: 10.1186/s13024-025-00827-y.
2
Immune mechanisms and shared immune targets in neurodegenerative diseases.神经退行性疾病中的免疫机制和共同免疫靶点
Nat Rev Neurol. 2025 Feb;21(2):67-85. doi: 10.1038/s41582-024-01046-7. Epub 2024 Dec 16.
3
Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson's Disease: A Possible Factor Influencing Clinical Phenotype?脑源性甾体水平在 GBA 突变和非突变帕金森病中的变化:影响临床表型的可能因素?

本文引用的文献

1
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.LRRK2(富含亮氨酸重复激酶 2)和 GBA(β-葡糖苷脂酶)帕金森病患者的临床和多巴胺转运体成像特征:帕金森进展标志物倡议的横断面研究。
Mov Disord. 2020 May;35(5):833-844. doi: 10.1002/mds.27989. Epub 2020 Feb 19.
2
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.帕金森进展标志物倡议(PPMI)中无明显 LRRK2 和 GBA 突变携带者的临床和多巴胺转运体成像特征:一项横断面研究。
Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.
3
Biomolecules. 2024 Aug 17;14(8):1022. doi: 10.3390/biom14081022.
4
Gaucher disease provides a unique window into Parkinson disease pathogenesis.戈谢病为帕金森病发病机制的研究提供了一个独特的窗口。
Nat Rev Neurol. 2024 Sep;20(9):526-540. doi: 10.1038/s41582-024-00999-z. Epub 2024 Aug 6.
5
The immune system in Parkinson's disease: what we know so far.帕金森病中的免疫系统:目前我们所知的。
Brain. 2024 Oct 3;147(10):3306-3324. doi: 10.1093/brain/awae177.
6
Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery.溶酶体储存、自噬和先天免疫在 Gaucher 和帕金森病中的作用:药物发现的新视角。
Philos Trans R Soc Lond B Biol Sci. 2024 Apr 8;379(1899):20220381. doi: 10.1098/rstb.2022.0381. Epub 2024 Feb 19.
7
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.帕金森病前驱期和早期的影像学生物标志物。
J Parkinsons Dis. 2024;14(s2):S353-S365. doi: 10.3233/JPD-230385.
8
What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?炎症能告诉我们哪些关于帕金森病治疗策略的信息?
Int J Mol Sci. 2024 Jan 29;25(3):1641. doi: 10.3390/ijms25031641.
9
Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.抑制半胱氨酸蛋白酶组织蛋白酶 L 会增加溶酶体葡萄糖脑苷脂酶的水平和活性。
JCI Insight. 2024 Feb 8;9(3):e169594. doi: 10.1172/jci.insight.169594.
10
Autophagic dysfunction and gut microbiota dysbiosis cause chronic immune activation in a Drosophila model of Gaucher disease.自噬功能障碍和肠道微生物群落失调导致戈谢病果蝇模型中的慢性免疫激活。
PLoS Genet. 2023 Dec 21;19(12):e1011063. doi: 10.1371/journal.pgen.1011063. eCollection 2023 Dec.
Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.GBA1 携带者前驱帕金森特征的演变和聚类。
Mov Disord. 2019 Sep;34(9):1365-1373. doi: 10.1002/mds.27775. Epub 2019 Jun 28.
4
Evolution of prodromal parkinsonian features in a cohort of mutation-positive individuals: a 6-year longitudinal study.队列研究中突变阳性个体前驱帕金森特征的演变:一项 6 年纵向研究。
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1091-1097. doi: 10.1136/jnnp-2019-320394. Epub 2019 Jun 20.
5
Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.特发性快速眼动睡眠行为障碍患者的神经炎症评估:病例对照研究。
Lancet Neurol. 2017 Oct;16(10):789-796. doi: 10.1016/S1474-4422(17)30173-4. Epub 2017 Jul 3.
6
Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.脑炎症伴随着阿尔茨海默病导致的大多数轻度认知障碍病例中的淀粉样蛋白。
Brain. 2017 Jul 1;140(7):2002-2011. doi: 10.1093/brain/awx120.
7
An early and late peak in microglial activation in Alzheimer's disease trajectory.阿尔茨海默病病程中微胶质细胞激活的早期和晚期峰值。
Brain. 2017 Mar 1;140(3):792-803. doi: 10.1093/brain/aww349.
8
Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.GBA 相关帕金森病的生存和痴呆:突变很重要。
Ann Neurol. 2016 Nov;80(5):662-673. doi: 10.1002/ana.24777. Epub 2016 Oct 3.
9
Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.阿尔茨海默病中早期和保护性的小胶质细胞激活:使用 18F-DPA-714 PET 成像的前瞻性研究。
Brain. 2016 Apr;139(Pt 4):1252-64. doi: 10.1093/brain/aww017. Epub 2016 Mar 15.
10
MDS research criteria for prodromal Parkinson's disease.前驱期帕金森病的MDS研究标准。
Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431.